Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATR"mTOR inhibitor drug candidates. It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies. Additionally, Rakovina Therapeutics Inc. has a strategic collaboration with Celvion Therapeutics to identify novel precision medicine strategies. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does RKVTF (RKVTF) operate in?
RKVTF belongs to the Other sector and operates in the Biotechnology industry.
What is RKVTF (RKVTF) current stock price?
As of the latest data, RKVTF stock price is $0.12, with a previous close of $0.12.
What is RKVTF (RKVTF) current market capitalization?
RKVTF market cap is approximately 3.00 million.
What is RKVTF (RKVTF) Earnings Per Share (EPS)?
The trailing EPS is -$0.22.
What is RKVTF (RKVTF) EBITDA?
RKVTF EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.01 million.
Does RKVTF (RKVTF) pay dividends?
No. RKVTF does not pay a dividend.
What is RKVTF (RKVTF) beta (volatility) score?
RKVTF has a beta of -0.241, indicating lower volatility than the overall market.
